Loading
A phase 2 trial of Emapalumab, Cyclophosphamide, Fludarabine and Axicabtagene ciloleucel in Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Primary mediastinal and Follicular lymphoma, run by Marcela V. Maus, M.D.,Ph.D., now recruiting.
Emapalumab Prevention of CAR-T Cell Associated Toxicities is a phase 2 interventional study registered as NCT06550141 by Marcela V. Maus, M.D.,Ph.D., with 28 participants planned, started 2024-09-18 and due to reach its primary completion in 2026-08-01. Interventions recorded: Emapalumab, Cyclophosphamide, Fludarabine Phosphate, Axicabtagene Ciloleucel. Conditions recorded: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma.
Linked to the drug Emapalumab because the registry names it among its interventions and Non-Hodgkin lymphoma, Diffuse large B-cell lymphoma, Primary mediastinal and Follicular lymphoma among its conditions. Registry record only: no result has been read by an editor.
Shares Emapalumab and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Fludarabine, Cyclophosphamide, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Diffuse large B-cell lymphoma and the tag pipeline.